Predicting risk factors for hypothyroidism after definitive radiotherapy for early glottic carcinomas

Okubo,Mitsuru; Itonaga,Tomohiro; Saito,Tatsuhiko; Yunaiyama,Daisuke; Mikami,Ryuji; Okada,Yukinori; Sugahara,Shinji; Kondo,Takahito; Tokuuye,Koichi; Saito,Kazuhiro

doi:10.3892/ol.2022.13603

Predicting risk factors for hypothyroidism after definitive radiotherapy for early glottic carcinomas

Authors:
- Mitsuru Okubo
- Tomohiro Itonaga
- Tatsuhiko Saito
- Daisuke Yunaiyama
- Ryuji Mikami
- Yukinori Okada
- Shinji Sugahara
- Takahito Kondo
- Koichi Tokuuye
- Kazuhiro Saito
View Affiliations

Affiliations: Department of Radiology, Tokyo Medical University Hospital, Tokyo 160‑0023, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo 193‑0998, Japan
Published online on: November 21, 2022 https://doi.org/10.3892/ol.2022.13603
Article Number: 17
Copyright: © Okubo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypothyroidism may occur after definitive radiotherapy in rare cases of early glottic carcinoma. However, to the best of our knowledge, no study to date has examined the risk factors for hypothyroidism specifically after definitive radiotherapy in patients with early glottic carcinoma. The present study determined risk factors for hypothyroidism after definitive radiotherapy in patients with early glottic carcinoma. This was a retrospective study that included 73 patients with T1 or T2, N0 glottic squamous cell carcinoma who underwent radiotherapy between June 3, 2009 and December 25, 2020. Demographic and clinical characteristics, including age, sex, tumor stage and pretreatment thyroid volume, were examined to elucidate the clinical risk factors for hypothyroidism. Field size, total prescribed dose and thyroid receiving dose were evaluated as dosimetric risk factors for hypothyroidism. Irradiated underlying thyroid volumes of more than 5, 10, 20, 30, 40, 50, 60 and 65 Gy (V5Gy, V10Gy, V20Gy, V30Gy, V40Gy, V50Gy, V60Gy and V65Gy) and mean thyroid dose were included as thyroid receiving doses. The median follow‑up duration was 61 months (range, 7‑150 months). Hypothyroidism was present in 15 (21%) of the 73 patients, including 12 and 3 patients with grade 1 and 2 hypothyroidism, respectively. Among the demographic and clinical factors, sex and pretreatment thyroid volume were significantly associated with hypothyroidism (P=0.007 and P<0.001, respectively). Among the dosimetric factors, the presence of hypothyroidism was significantly associated with V5Gy (P=0.012), V10Gy (P=0.015), V20Gy (P=0.020), V30Gy (P=0.024), V40Gy (P=0.028), V50Gy (P=0.028), V60Gy (P=0.027) and mean thyroid dose (P=0.023). In conclusion, sex, pretreatment thyroid volume and thyroid receiving dose were associated with hypothyroidism after definitive radiotherapy in patients with early glottic carcinoma. Particularly, the receiving dose to the thyroid gland should be reduced in female patients and in those with small thyroid volumes who are at higher risk for hypothyroidism following radiotherapy.

View Figures

View References

1	Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ and Villaret DB: Management of T1-T2 glottic carcinomas. Cancer. 100:1786–1792. 2004. View Article : Google Scholar : PubMed/NCBI
2	Beitler JJ and Johnson JT: Transoral laser excision for early glottic cancer. Int J Radiat Oncol Biol Phys. 56:1063–1066. 2003. View Article : Google Scholar : PubMed/NCBI
3	Back G and Sood S: The management of early laryngeal cancer: Options for patients and therapists. Curr Opin Otolaryngol Head Neck Surg. 13:85–91. 2005. View Article : Google Scholar : PubMed/NCBI
4	Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L and Laurberg P: Gender differences in symptoms of hypothyroidism: A population-based DanThyr study. Clin Endocrinol (Oxf). 83:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
5	Floriani C, Gencer B, Collet TH and Rodondi N: Subclinical thyroid dysfunction and cardiovascular diseases: 2016 Update. Eur Heart J. 39:503–507. 2018. View Article : Google Scholar : PubMed/NCBI
6	Biondi B, Cappola AR and Cooper DS: Subclinical hypothyroidism: A review. JAMA. 322:153–160. 2019. View Article : Google Scholar : PubMed/NCBI
7	Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, et al: Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 304:1365–1374. 2010. View Article : Google Scholar : PubMed/NCBI
8	Okubo M, Itonaga T, Saito T, Shiraishi S, Mikami R, Sakurada A, Sugahara S, Park J, Tokuuye K and Saito K: Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy. Mol Clin Oncol. 12:541–550. 2020.PubMed/NCBI
9	Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J and Fong KW: Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 98:574–580. 2017. View Article : Google Scholar : PubMed/NCBI
10	Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW and Lee A: Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 28:e52–e60. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lertbutsayanukul C, Kitpanit S, Prayongrat A, Kannarunimit D, Netsawang B and Chakkabat C: Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a phase III randomized trial. J Radiat Res. 59:446–455. 2018. View Article : Google Scholar : PubMed/NCBI
12	Fan CY, Lin CS, Chao HL, Huang WY, Su YF, Lin KT, Tsai IJ and Kao CH: Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A population-based cohort study. Radiother Oncol. 123:394–400. 2017. View Article : Google Scholar : PubMed/NCBI
13	Luo R, Li M, Yang Z, Zhan Y, Huang B, Lu J, Xu Z and Lin Z: Nomogram for radiation-induced hypothyroidism prediction in nasopharyngeal carcinoma after treatment. Br J Radiol. 90:201606862017. View Article : Google Scholar : PubMed/NCBI
14	Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, et al: Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol. 19:800–811. 2001. View Article : Google Scholar : PubMed/NCBI
15	Tell R, Lundell G, Nilsson B, Sjödin H, Lewin F and Lewensohn R: Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 60:395–400. 2004. View Article : Google Scholar : PubMed/NCBI
16	Tell R, Sjödin H, Lundell G, Lewin F and Lewensohn R: Hypothyroidism after external radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 39:303–308. 1997. View Article : Google Scholar : PubMed/NCBI
17	Ling S, Bhatt AD, Brown NV, Nguyen P, Sipos JA, Chakravarti A and Rong Y: Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation. Head Neck. 39:548–554. 2017. View Article : Google Scholar : PubMed/NCBI
18	Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, et al: Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 77:468–476. 2010. View Article : Google Scholar : PubMed/NCBI
19	Grande C: Hypothyroidism following radiotherapy for head and neck cancer: Multivariate analysis of risk factors. Radiother Oncol. 25:31–36. 1992. View Article : Google Scholar : PubMed/NCBI
20	Boomsma MJ, Bijl HP and Langendijk JA: Radiation-induced hypothyroidism in head and neck cancer patients: A systematic review. Radiother Oncol. 99:1–5. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhai RP, Kong FF, Du CR, Hu CS and Ying HM: Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 68:44–49. 2017. View Article : Google Scholar : PubMed/NCBI
22	Vogelius IR, Bentzen SM, Maraldo MV, Petersen PM and Specht L: Risk factors for radiation-induced hypothyroidism: A literature-based meta-analysis. Cancer. 117:5250–5260. 2011. View Article : Google Scholar : PubMed/NCBI
23	Sachdev S, Refaat T, Bacchus ID, Sathiaseelan V and Mittal BB: Thyroid V50 highly predictive of hypothyroidism in head-and-neck cancer patients treated with intensity-modulated radiotherapy (IMRT). Am J Clin Oncol. 40:413–417. 2017. View Article : Google Scholar : PubMed/NCBI
24	Rønjom MF, Brink C, Bentzen SM, Hegedüs L, Overgaard J and Johansen J: Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: Normal tissue complication probability modeling with latent time correction. Radiother Oncol. 109:317–322. 2013. View Article : Google Scholar : PubMed/NCBI
25	Heidari S, Babor TF, De Castro P, Tort S and Curno M: Sex and gender equity in research: Rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 1:22016. View Article : Google Scholar : PubMed/NCBI
26	Steuer CE, El-Deiry M, Parks JR, Higgins KA and Saba NF: An update on larynx cancer. CA Cancer J Clin. 67:31–50. 2017. View Article : Google Scholar : PubMed/NCBI